Clinical trialPhase 2Terminated
Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
- Outcome
- Stopped earlyPI departure from institution (Other)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 31 July 2018
- Expected end
- 15 June 2020
- Enrollment
- 7 participants
- Sites
- 2
- Primary outcomes
- Number of Participants With Incidence of Unacceptable Toxicity; Number of Participants Who Proceeded to Surgical Resection
- Sponsor
- Other
- Results posted
- 2021-10-19
- Last update
- 19 October 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
A multi-institutional, single arm phase II study of nivolumab, cabiralizumab and stereotactic body radiotherapy (SBRT) in patients with LAUPC. The purpose of this study is to determine the safety and tolerability of combined cabiralizumab, nivolumab and radiotherapy in the treatment of locally advanced pancreatic cancer. Investigators will also estimate the surgical resection rate following treatment with combined cabiralizumab, nivolumab and radiotherapy in subjects with locally advanced unresectable pancreatic cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants With Incidence of Unacceptable Toxicity [24 Months]. Count Of Participants, Participants. Multi Agent Chemotherapy Cancer Patients (n=4): 4.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Number of Participants Who Proceeded to Surgical Resection [24 Months]. Count Of Participants, Participants. Multi Agent Chemotherapy Cancer Patients (n=4): 1.